STOCK INFO
FUNDAMENTALS
EARNINGS
OPTIONS
COMPANY INFO
LINKS
Iovance Biotherapeutics (IOVA) compared side by side with its peers: income and expenses, growth rates, profitability, stock performance and valuation ratios.
Compare the fundamental data of IOVA with symbols that are considered similar or are in the same peer group.
▲ Close
| IOVA | Median of Peers | |
|---|---|---|
| Market Cap | 6.1 B | - |
| Revenue | 325.0 M | - |
| Cost of Revenue | 167.7 M | - |
| Gross Profit | 157.3 M | - |
| Operating Expense | 453.5 M | - |
| Selling and General Admin | 149.2 M | - |
| Selling and Marketing | 0.0 | - |
| Research and Development | 267.7 M | - |
| Operating Income | -296.2 M | - |
| Net Income to Shareholders | -289.5 M | - |
| IOVA | Median of Peers | |
|---|---|---|
| Market Cap | 6.1 B | - |
| Revenue | 100.0% | - |
| Cost of Revenue | 51.6% | - |
| Gross Profit | 48.4% | - |
| Operating Expense | 139.5% | - |
| Selling and General Admin | 45.9% | - |
| Selling and Marketing | 0.0% | - |
| Research and Development | 82.4% | - |
| Operating Income | -91.1% | - |
| Net Income to Shareholders | -89.1% | - |
| IOVA | Median of Peers | |
|---|---|---|
| Market Cap | 6.1 B | - |
| Revenue | 34.5% | - |
| Cost of Revenue | -12.6% | - |
| Gross Profit | 216.1% | - |
| Operating Expense | -1.5% | - |
| Selling and General Admin | -8.9% | - |
| Selling and Marketing | - | - |
| Research and Development | -9.8% | - |
| Operating Income | - | - |
| Net Income to Shareholders | - | - |
| IOVA | Median of Peers | |
|---|---|---|
| Market Cap | 6.1 B | - |
| Revenue | 5.3% | - |
| Cost of Revenue | 2.8% | - |
| Gross Profit | 2.6% | - |
| Operating Expense | 7.5% | - |
| Selling and General Admin | 2.5% | - |
| Selling and Marketing | 0.0% | - |
| Research and Development | 4.4% | - |
| Operating Income | -4.9% | - |
| Net Income to Shareholders | -4.8% | - |
Total Return over time For IOVA, including dividends
| Duration | IOVA | Median of Peers |
|---|---|---|
| Today | -7.5% | - |
| 2 Week | -4.2% | - |
| 1 Month | +38.0% | - |
| 3 Month | +192.3% | - |
| 6 Month | +258.4% | - |
| 1 Year | +508.0% | - |
| YTD | +398.9% | - |
| 3 Year | +281.5% | - |
| 5 Year | -48.8% | - |
| Valuation Ratios | IOVA | Median of Peers |
|---|---|---|
|
P/E Ratio:
Ratio Price/Earnings. Common valuation ratio measures the price of the stock relative to how much earnings the company generates per share.
|
- | |
|
P/E Normalized EPS:
Price/TTM normalized diluted earnings per share. This calculation reverses the effects of extraordinary income or charges on Net Income, by adding back (extraordinary expense) or subtracting (extraordinary income) the value from Net Income
|
- | |
|
Price/Sales:
Ratio Price/Revenue |
17.19 | - |
|
Price/Book Value:
Ratio Price/Book Value. Book Value is Common Shareholder’s Equity / Diluted Shares Outstanding. |
8.53 | - |
|
Price/Tangible Book Value:
Ratio price/Tangible book value. Tangible Book Value is The company’s total book value less the value of any intangible assets dividend by number of shares. |
13.44 | - |
|
PEG Ratio:
Forward PE Ratio / Long-term Average Earning Growth Rate. Peg ratio is a version of a P/E ratio using an estimated forward earnings taking into consideration earnings growth estimates. |
- | |
| Price/Cash: | 55.70 | - |
|
Price/Free Cash Flow:
Ratio Price/Free Cash Flow. Free Cash Flow is Cash Flow Operations plus Capital Expenditures. Free cash flow is the cash from operations left over after the company pays for its operating and capital expenses. |
- | |
|
Price/Ebitda:
Ratio Price/Ebitda. Ebitda is Earnings minus expenses (excluding interest, tax, depreciation, and amortization expenses). |
- | |
|
Price/Ebit:
Ratio Price/Ebit. Ebit is Earnings minus expenses (excluding interest and tax expenses). |
- | |
|
Price/Working Capital:
Ratio Price/Working Capital. Working Capital is Current Assets minus Current Liabilities. |
17.26 | - |
|
Forward PE Ratio:
1 / ForwardEarningYield. Forward Yield: Estimated Earnings Per Share / Price. EPS is estimated for next year.
|
- | |
|
PEG Pay Back:
The number of years it would take for a company's cumulative earnings to equal the stock's current trading price, assuming that the company continues to increase its annual earnings at the growth rate used to calculate the PEG ratio.
|
- | |
|
Price/CFO:
Ratio Price/Cash Flow from Operations: Cash Flow from Operations is the amount of money a company generates on a regular basis from its business activity. Excludes any one time activity.
|
- | |
|
EV to EBITDA:
Ratio Enterprise Value/Earnings Before Interest, Taxes and depreciation and amortization. |
- |
| Symbol | Name | Current Price |
Current % Chg |
Market Cap | About | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
